CLEC9A and cancer: There is an increasing evidence that these therapies work not only by directly killing cancer cells but also by inducing or boosting antitumor immune responses.11–13 We; therefore, hypothesized that therapy-induced cell death would increase the antigenic visibility of tumors, augmenting DNGR-1 triggering by F-actin in sGsn–/– mice and resulting in improved anticancer immunity.